This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
TG Therapeutics (TGTX) Misses Q2 Earnings Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -46.88% and +3.75%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q2 Release
by Zacks Equity Research
TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in TG Therapeutics Stock?
by Zacks Equity Research
Investors need to pay close attention to TGTX stock based on the movements in the options market lately.
Should First Trust Small Cap Core AlphaDEX ETF (FYX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYX
TG Therapeutics (TGTX) Lags Q1 Earnings Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -83.33% and 1.99%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alnylam (ALNY) delivered earnings and revenue surprises of 98.21% and 1.02%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is First Trust Small Cap Core AlphaDEX ETF (FYX) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FYX
TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why
by Zacks Equity Research
Strong adoption of TGTX's sole marketed product, Briumvi, approved for treating relapsing forms of multiple sclerosis, is driving the top line.
Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength?
by Zacks Equity Research
TG Therapeutics (TGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Company News for Mar 4, 2025
by Zacks Equity Research
Companies In The News Are: CRC, TGTX, NOMD, BHVN.
Novavax to Report Q4 Earnings: Here's What You Can Expect
by Zacks Equity Research
On NVAX's fourth-quarter earnings call, investors will likely focus on updates on its pipeline.
BioMarin to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
When BMRN reports fourth-quarter earnings, investors will likely focus on the sales performance of its dwarfism drug Voxzogo.
All You Need to Know About TG Therapeutics (TGTX) Rating Upgrade to Buy
by Zacks Equity Research
TG Therapeutics (TGTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise
by Zacks Equity Research
TG Therapeutics reports preliminary fourth-quarter and full-year 2024 product revenues. It also provides revenue guidance for 2025 and other pipeline goals.
TG Therapeutics (TGTX) Moves 7.5% Higher: Will This Strength Last?
by Zacks Equity Research
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
TG Therapeutics (TGTX) Lags Q3 Earnings Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -50% and 4.46%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Stock Market News for Aug 7, 2024
by Zacks Equity Research
Wall Street bounced back from a three-day rout to end higher on Tuesday as investors paused concerns about an impending recession.
TG Therapeutics (TGTX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of 200% and 11.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics (TGTX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -133.33% and 15.59%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
After Plunging -9.82% in 4 Weeks, Here's Why the Trend Might Reverse for TG Therapeutics (TGTX)
by Zacks Equity Research
TG Therapeutics (TGTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Company News for Feb 29, 2024
by Zacks Equity Research
Companies In The Article Are:TSLA, URBN, BYND and TGTX
TG Therapeutics (TGTX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of 25% and 9.72%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?